Zura Bio LTD 8-K filings

Zura Bio announced the completion of enrollment for its TibuSHIELD and TibuSURE Phase 2 studies, with topline data expected in Q4 2026 and H1 2027, respectively, and plans to initiate a new Phase 2 study for tibulizumab in polymyalgia rheumatica by year-end 2026.

Zura Bio Limited has released an updated corporate presentation detailing its lead drug candidate, tibulizumab, and its ongoing clinical trials for complex immune disorders.

Zura Bio Limited shareholders approved an amended equity incentive plan and elected directors at the company's Annual General Meeting.

Zura Bio announced first quarter 2026 financial results, highlighting progress in its Phase 2 studies for tibulizumab and a strengthened financial position.

Zura Bio announces the departure of CFO Eric Hyllengren and the appointment of Marlyn Mathew as his successor.

Zura Bio Limited announced its full fiscal year 2025 financial results and provided updates on its clinical programs, including a strengthened balance sheet and anticipated Phase 2 data readouts.

Zura Bio Limited announced it will present the design of its ongoing Phase 2 TibuSURE clinical trial for systemic sclerosis at the 9th Systemic Sclerosis World Congress.

Zura Bio Limited filed an amendment to its 8-K report, updating legal opinions related to the issuance of Class A ordinary shares and pre-funded warrants.

Zura Bio Limited announced the pricing of a public offering of Class A ordinary shares and pre-funded warrants, expecting to raise $125 million in gross proceeds to advance its clinical-stage immunology pipeline.

Zura Bio Limited announced the appointment of Dr. Mark Eisner and Dr. Ajay Nirula to its Board of Directors, effective February 21, 2026, following the resignation of Dr. Neil Graham.

Zura Bio Limited provided an updated corporate presentation detailing its lead bispecific antibody, tibulizumab, and its ongoing Phase 2 trials for hidradenitis suppurativa and systemic sclerosis.

Zura Bio Limited announced the appointment of Dr. Sandeep Kulkarni as its new Chief Executive Officer, succeeding Robert Lisicki, and welcomed Parvinder Thiara back to its Board of Directors.

Zura Bio Limited provided an updated corporate presentation and press release detailing clinical trial progress for tibulizumab in hidradenitis suppurativa and systemic sclerosis, alongside a strong cash runway through 2027.

Zura Bio Limited has terminated previous agreements with Stone Peach and BAFFX17, entering into new, more commercially advantageous terms with Athanor Capital, involving a share issuance and significant payments.

Zura Bio Limited announced the immediate resignation of Arnout Ploos van Amstel from its Board of Directors and Nominating and Governance Committee.

Zura Bio Limited announced its third quarter 2025 financial results, highlighting continued progress in its Phase 2 clinical trials for tibulizumab and a strong cash position expected to fund operations through 2027.

Zura Bio Limited announced that CEO Robert Lisicki is taking a medical leave of absence, with Kim Davis appointed as interim CEO.

Zura Bio Limited's Board of Directors approved an Executive Severance Benefit Plan, providing severance packages for eligible executives upon certain involuntary terminations or resignations for good reason.

Zura Bio Limited provided an updated corporate presentation highlighting progress in its dual-pathway biologic candidates for autoimmune and inflammatory diseases, with key clinical data expected in late 2026.

Zura Bio Limited announced its senior leadership will participate in a fireside chat and investor meetings at the Cantor Fitzgerald Global Healthcare Conference on September 4, 2025.

Zura Bio announced its second quarter 2025 financial results, highlighting progress in its Phase 2 clinical studies for autoimmune diseases and a strong cash position.

Zura Bio Limited announced the appointment of Eric Hyllengren as its new Chief Financial Officer, effective July 7, 2025, succeeding Verender Badial who will transition out of the role.

Zura Bio Limited presented an updated corporate overview at the Jefferies Global Healthcare Conference, emphasizing its pipeline of dual-pathway biologic candidates for autoimmune and inflammatory diseases, with key Phase 2 data expected in 2026.

Zura Bio Limited, a clinical-stage immunology company, announced its senior leadership will present a corporate overview and hold one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2025.

Zura Bio Limited held its Annual General Meeting on May 21, 2025, and shareholders voted on the election of directors, ratification of the accounting firm, and a proposal for adjournment.

Zura Bio initiates a global Phase 2 clinical trial, TibuSHIELD, to evaluate tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS).

Zura Bio announced its Q1 2025 financial results, highlighting progress in clinical trials and a strong cash position.

Zura Bio Limited has entered into agreements with Venrock Healthcare Capital Partners and AI Biotechnology, LLC, resulting in the surrender of 6.5 million shares and the issuance of warrants to purchase the same number of shares.

Zura Bio updates investors on its pipeline of dual-pathway biologics targeting autoimmune and inflammatory diseases, with key milestones anticipated over the next 36 months.

Zura Bio announces its full year 2024 financial results, highlighting key clinical milestones and a strong cash position extending into 2027.